Augmedix (AUGX) to Release Quarterly Earnings on Monday

Augmedix (NASDAQ:AUGX) is scheduled to issue its quarterly earnings data after the market closes on Monday, August 12th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Augmedix has set its FY 2024 guidance at EPS.

Augmedix (NASDAQ:AUGX) last posted its earnings results on Monday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). Augmedix had a negative return on equity of 178.34% and a negative net margin of 41.95%. The business had revenue of $13.47 million during the quarter, compared to analyst estimates of $13.25 million.

Augmedix Stock Up 0.9 %

Shares of AUGX stock traded up $0.02 during trading hours on Wednesday, reaching $2.26. The company had a trading volume of 56,110 shares, compared to its average volume of 755,915. The company has a debt-to-equity ratio of 0.73, a quick ratio of 2.04 and a current ratio of 2.04. Augmedix has a twelve month low of $0.73 and a twelve month high of $6.25. The company has a market capitalization of $110.67 million, a P/E ratio of -5.21 and a beta of -0.22. The stock’s fifty day simple moving average is $1.24 and its 200 day simple moving average is $2.73.

Analysts Set New Price Targets

AUGX has been the subject of a number of recent research reports. B. Riley lowered Augmedix from a “strong-buy” rating to a “hold” rating and lowered their target price for the company from $3.00 to $2.35 in a research note on Friday, July 19th. Maxim Group downgraded Augmedix from a “buy” rating to a “hold” rating and set a $5.00 price target for the company. in a report on Tuesday, May 14th. Lake Street Capital reissued a “hold” rating on shares of Augmedix in a report on Monday, July 22nd. William Blair downgraded Augmedix from a “strong-buy” rating to a “hold” rating in a report on Friday, July 19th. Finally, Evercore ISI downgraded Augmedix from an “outperform” rating to an “inline” rating and reduced their price target for the company from $5.00 to $1.50 in a report on Tuesday, May 14th. Four investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Augmedix presently has a consensus rating of “Hold” and a consensus price target of $3.09.

About Augmedix

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.